EXHIBIT 10.13
CERTAIN PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED BASED UPON A REQUEST FOR
CONFIDENTIAL TREATMENT.
AMENDMENT NO. 1 TO LICENSE AGREEMENT
THIS AMENDMENT NO. 1 TO LICENSE AGREEMENT is made as of the 6th day of
September, 2002 by and between BENTLEY PHARMACEUTICALS, INC., a Delaware
corporation, with offices at 00 Xxxxxxxxx Xxxx, 0xx Xxxxx, Xxxxx Xxxxxxx, Xxx
Xxxxxxxxx 03862-2403 (hereinafter, "BENTLEY" or "Licensor"), and AUXILIUM
PHARMACEUTICALS, INC. (formerly Auxilium A(2), Inc.), a Delaware corporation
having a principal place of business at 000 X. Xxxxxxxxxx Xxxx, Xxxxx X-0, Xxxx
Xxxxxxxx, Xxxxxxxxxxxx 00000 (hereinafter, "AUXILIUM" or "Licensee"). BENTLEY
and AUXILIUM may be referred to as a "Party" or, collectively, as "Parties."
RECITALS
WHEREAS the parties have entered into that certain License Agreement, dated May
31, 2001, relating to the grant by BENTLEY to AUXILIUM of a license of certain
technology which relates to formulations which contain the therapeutic drug
dihydrotestosterone and CPE-215 (the "License Agreement"); and
WHEREAS, BENTLEY would like to provide incentives to AUXILIUM to enter into
sub-licenses for the Products in territories outside the United States; and
WHEREAS, BENTLEY would like to provide further incentives to AUXILIUM to extend
the commercial life of the Products licensed under the License Agreement; and
WHEREAS the Parties wish to further amend the License Agreement to change
certain sections of the License Agreement;
NOW, THEREFORE, in consideration of the promises and mutual covenants contained
herein, and INTENDING TO BE LEGALLY BOUND HEREBY, the Parties further amend the
License Agreement as follows:
ARTICLE I
DEFINITIONS
1.1 Except as amended below, the terms defined in the License Agreement shall
remain unchanged. Unless otherwise defined in this Amendment, all
capitalized terms in this Amendment shall have the meanings ascribed to
them in the License Agreement, as amended by the Previous Amendments.
ARTICLE III
PAYMENTS IN CONSIDERATION FOR LICENSE
3.1 Except as amended below, all payments set forth in Article III of the
License Agreement shall remain unchanged.
3.2 (a) of the License Agreement shall be amended to read as follows:
(a) there is an enforceable BENTLEY Patent at the time of sale:
All Annual Net Sales in the United *
States and Canada
All Annual Net Sales outside the *
United States and Canada
"Product Royalties" shall mean all payments received by Auxilium which
are based on sales of Products, but shall not include milestone
payments related to achievements which are not sales based.
ARTICLE IV
INTELLECTUAL PROPERTY
4.1 Article VIII of the License Agreement is amended in its entirety to read as
follows:
8.1 Intellectual Property Rights. The inventorship of inventions
developed under this Agreement and relating to Products ("Inventions")
shall be determined in accordance with U.S. Law. Inventions made
solely by employees of BENTLEY or owned by BENTLEY ("BENTLEY
Inventions") shall be the exclusive property of BENTLEY. Inventions
made solely by employees of AUXILIUM ("AUXILIUM Inventions") shall be
the exclusive property of AUXILIUM, except that AUXILIUM Inventions
that relate to the use of Products shall be owned by BENTLEY and shall
be included in the license granted under this License Agreement and
included in the definition of BENTLEY Patents. Inventions made by
employees of BENTLEY and employees of AUXILIUM shall also be owned by
BENTLEY and shall be included in the license granted under this
License Agreement and included in the definition of BENTLEY Patents.
* Confidential information has been omitted and filed confidentially with the
Securities and Exchange Commission.
2
IN WITNESS WHEREOF, the parties hereto have duly executed this Amendment
No. 1 to License Agreement as of the date first above written.
BENTLEY PHARMACEUTICALS, INC. AUXILIUM PHARMACEUTICALS, INC.
By: /s/ XXXXX X. XXXXXX By: /s/ XXXXXXXXX X. XXXXXXX
-------------------------------- ------------------------
Xxxxx X. Xxxxxx Xxxxxxxxx X. Xxxxxxx
Chief Executive Officer Chief Executive Officer
3
